- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Further information:
- selected
- Process:
- STA Standard
- ID number:
- 6480
Provisional Schedule
- Draft guidance:
- 23 July 2025 - 13 August 2025
- Committee meeting: 2:
- 03 September 2025
- Expected publication:
- 29 October 2025
Project Team
- Project lead
- Thomas Feist
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- BMJ Technology Assessment Group (BMJ-TAG), BMJ
Stakeholders
- Companies sponsors
- Sanofi (dupilumab)
- Others
- Department of Health and Social Care
- Health Technology Wales (HTW)
- NHS England
- Patient carer groups
- Fifth Sense
- Sinus UK
- Professional groups
- Association of Respiratory Nurse Specialists
- Royal College of Physicians
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- None
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 02 July 2025 | Committee meeting: 1 |
| 02 July 2025 | Declaration of interests |
| 19 November 2024 | Invitation to participate |
| 19 November 2024 | In progress |
| 22 October 2024 - 05 November 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual